The Buzz PB 3 Sarm Stack
£69.99
- High dose : 15mg MK677, 15mg Ostarine and 15mg Rad140 per serving!
- Increased Strength
- Increased Muscle size
- Increased Glycogen Retention
- Enhanced Recovery
- Increased Appetite
In stock
Free Shipping Over £50 (UK)
- Free Worldwide Shipping Over £100
- Fast Delivery
- Secure Payments
- Satisfaction Guaranteed
The Buzz PB 3 Sarm Stack
It’s time to set a new personal best. PB is the ultimate blend of MK677, Ostarine and Rad140 for gaining mass and strength, while keeping body fat under control. Improve your training, recovery, appetite and sleep with The Buzz! PB. It contains 15mg of each compounds which makes it very potent and definitely not for first time users!
KEY BENEFITS
- Increased Strength
- Increased Muscle size
- Increased Glycogen Retention
- Enhanced Recovery
- Increased Appetite
Nutrition Information
Serving – 2 capsules
Ostarine 15mg
MK677 15mg
RAD140 15mg
Suggested use
Use 2 capsules in the morning upon waking.
About Ingredients
MK-677 binds to ghrelin receptors on the surfaces of cells. This triggers a series of chain reactions including increased secretion of several hormones such as GH and insulin-like growth factor (IGF-1).
RAD-140 a potent selective androgen receptor modulator supplement (SARM) scientifically proven to increase lean muscle mass, stamina and strength without the side effects usually seen with steroid use. RAD-140 is more anabolic than testosterone and has a 90:1 ratio of anabolic to androgenic action making RAD-140 one of the most sought after SARM’S on the market.
Ostarine is the most anabolic SARM of them all making it the original go to for people looking to increase muscle mass rapidly without the use of steroids. When bulking we often see people gaining around 5-7lbs and sometimes more in a 6-week cycle. It can however be ran for a maximum of 12 weeks without the on cycle side effects associated with steroid use.
Additional information
Product Filter (SARMS) | Ibutamoren MK-677, Ostarine MK-2866, RAD 140 |
---|
Reviews
There are no reviews yet.